[go: up one dir, main page]

WO2002005850A3 - Enhancement of the action of anti-infective agents - Google Patents

Enhancement of the action of anti-infective agents Download PDF

Info

Publication number
WO2002005850A3
WO2002005850A3 PCT/ZA2001/000098 ZA0100098W WO0205850A3 WO 2002005850 A3 WO2002005850 A3 WO 2002005850A3 ZA 0100098 W ZA0100098 W ZA 0100098W WO 0205850 A3 WO0205850 A3 WO 0205850A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
group
agents
action
gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ZA2001/000098
Other languages
French (fr)
Other versions
WO2002005850A2 (en
Inventor
Petrus Johannes Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pitmy International NV
Original Assignee
Pitmy International NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pitmy International NV filed Critical Pitmy International NV
Priority to CA2416512A priority Critical patent/CA2416512C/en
Priority to AU2001283586A priority patent/AU2001283586A1/en
Publication of WO2002005850A2 publication Critical patent/WO2002005850A2/en
Publication of WO2002005850A3 publication Critical patent/WO2002005850A3/en
Priority to US10/345,204 priority patent/US8329685B1/en
Anticipated expiration legal-status Critical
Priority to US13/709,596 priority patent/US8937074B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the group comprising antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, characterised in that the agent is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5φ3], decosahexaenoic acid [C22: 6φ3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.
PCT/ZA2001/000098 2000-07-19 2001-07-19 Enhancement of the action of anti-infective agents Ceased WO2002005850A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2416512A CA2416512C (en) 2000-07-19 2001-07-19 Enhancement of the action of anti-infective agents
AU2001283586A AU2001283586A1 (en) 2000-07-19 2001-07-19 Enhancement of the action of anti-infective agents
US10/345,204 US8329685B1 (en) 2000-07-19 2003-01-16 Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
US13/709,596 US8937074B2 (en) 2000-07-19 2012-12-10 Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2000/3644 2000-07-19
ZA200003644 2000-07-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2001/000099 Continuation-In-Part WO2002005851A2 (en) 2000-07-19 2001-07-19 Enhancement of the action of central and peripheral nervous system agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/345,204 Continuation-In-Part US8329685B1 (en) 2000-07-19 2003-01-16 Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances

Publications (2)

Publication Number Publication Date
WO2002005850A2 WO2002005850A2 (en) 2002-01-24
WO2002005850A3 true WO2002005850A3 (en) 2003-01-09

Family

ID=25588833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2001/000098 Ceased WO2002005850A2 (en) 2000-07-19 2001-07-19 Enhancement of the action of anti-infective agents

Country Status (4)

Country Link
CN (1) CN100531799C (en)
AU (1) AU2001283586A1 (en)
CA (1) CA2416512C (en)
WO (1) WO2002005850A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000333A1 (en) 2002-06-20 2003-12-31 Astion Dermatology A/S Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
JP5159322B2 (en) * 2005-01-28 2013-03-06 ノース−ウエスト ユニヴァーシティ Adjuvants for enhancing vaccine efficacy
CN101426369A (en) * 2006-02-27 2009-05-06 西北大学 Microemulsion composition containing free fatty acids and/or free fatty acid derivatives
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN102293745B (en) * 2011-08-25 2013-03-13 西北农林科技大学 Natamycin nano-emulsion antifungal medicament and preparation method thereof
US10363324B2 (en) 2013-11-04 2019-07-30 The South African Nuclear Energy Corporation Limited Pharmaceutical composition
KR102364840B1 (en) * 2014-11-05 2022-02-18 삼성전자주식회사 Pharmaceutical composition for treating a disease associated with demyelination of neuron and method of using the same
CN105169368B (en) * 2015-09-16 2018-09-07 福建傲农生物科技集团股份有限公司 A kind of pharmaceutical composition for preventing piglet yellow-white dysentery
SE540411C2 (en) * 2016-01-27 2018-09-11 Ultupharma Ab New method of treating bacterial infections
GB201612093D0 (en) 2016-07-12 2016-08-24 Helperby Therapeutics Ltd Combination
KR20190039137A (en) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
CN109260152A (en) * 2018-11-13 2019-01-25 禹州市中医院 A kind of lomefloxacin hydrochloride auristilla
CN109937819A (en) * 2019-03-19 2019-06-28 湖南农业大学 A method for enhancing alkali tolerance of rice and increasing iron content in rice
CN120754078A (en) * 2024-07-30 2025-10-10 中山大学 Application of linoleic acid in preparation of medicines for improving sensitivity of gram-positive bacteria to antibiotics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025213A1 (en) * 1992-06-08 1993-12-23 Pitmy International N.V. Nitrous oxide containing dermatological composition
WO1997017978A1 (en) * 1995-11-13 1997-05-22 Pitmy International N.V. Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025213A1 (en) * 1992-06-08 1993-12-23 Pitmy International N.V. Nitrous oxide containing dermatological composition
WO1997017978A1 (en) * 1995-11-13 1997-05-22 Pitmy International N.V. Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs

Also Published As

Publication number Publication date
AU2001283586A1 (en) 2002-01-30
CN1458847A (en) 2003-11-26
CA2416512C (en) 2010-10-19
CA2416512A1 (en) 2002-01-24
WO2002005850A2 (en) 2002-01-24
CN100531799C (en) 2009-08-26

Similar Documents

Publication Publication Date Title
WO2002005851A3 (en) Enhancement of the action of central and peripheral nervous system agents
WO2002005850A3 (en) Enhancement of the action of anti-infective agents
NZ608755A (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
US11523999B2 (en) Compositions comprising a fatty aged oil mixture and a free fatty acid, and methods and uses thereof
Greenfield et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis
AU2010326054B2 (en) Substances for reducing occurrence of major cardiac events comprising red yeast rice and omega-3 polyunsaturated fatty acid or derivative thereof
WO2002067864A3 (en) Coenzyme q products exhibiting high dissolution qualities
HK57196A (en) Cyclosporin compositions for oral administration
ATE192647T1 (en) MEDICATIONS BASED ON DOCOSAHEXAENIC ACID, AS PLATELE AGGREGATION INHIBITORS AND AGAINST CEREBRAL DEFICIENCY OF FATTY ACIDS, AND METHOD FOR THE PRODUCTION.
US20110217275A1 (en) Compositions comprising probiotic bacteria of the strain bacillus coagulans and omega-3 polyunsaturated fatty acids or derivatives thereof
US20120201912A1 (en) Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract
ZA200608016B (en) Adjuvant for the enhancement of the efficacy of vaccines
HUP0303864A2 (en) Pharmaceutical composition based on macrolides for topical application in ophthalmology and process for its preparation
Cho et al. Compositional changes of functional oil from algae oil during the lipase-catalyzed production
WO2013138407A1 (en) Substances for reducing occurrence of major cardiac events comprising epa or derivatives thereof, optionally, dha or derivatives thereof and monacolin k
WO2013138411A1 (en) Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract
JPH04293991A (en) Antioxidant containing peridinin as effective constituent and manufacture of peridinin
HK1003385A (en) Esters of polyunsaturated fatty acids
HK1032744B (en) Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2003/00366

Country of ref document: ZA

Ref document number: 200300366

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2416512

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018157432

Country of ref document: CN

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP